The stock of Prothena Corporation PLC (NASDAQ:PRTA) is a huge mover today! About 639,301 shares traded hands or 66.17% up from the average. Prothena Corporation PLC (NASDAQ:PRTA) has risen 25.48% since April 8, 2016 and is uptrending. It has outperformed by 19.83% the S&P500.
The move comes after 9 months positive chart setup for the $2.40 billion company. It was reported on Nov, 10 by Barchart.com. We have $97.52 PT which if reached, will make NASDAQ:PRTA worth $1.56 billion more.
Prothena Corporation PLC (NASDAQ:PRTA) Ratings Coverage
Out of 5 analysts covering Prothena Corp (NASDAQ:PRTA), 5 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Prothena Corp has been the topic of 10 analyst reports since July 22, 2015 according to StockzIntelligence Inc. Barclays Capital maintained Prothena Corporation PLC (NASDAQ:PRTA) rating on Thursday, August 4. Barclays Capital has “Overweight” rating and $70 price target. RBC Capital Markets maintained Prothena Corporation PLC (NASDAQ:PRTA) on Thursday, November 19 with “Outperform” rating. The stock has “Buy” rating given by Deutsche Bank on Thursday, November 3. The firm earned “Outperform” rating on Friday, February 19 by Wedbush. The stock of Prothena Corporation PLC (NASDAQ:PRTA) has “Outperform” rating given on Tuesday, August 4 by Wedbush. The stock of Prothena Corporation PLC (NASDAQ:PRTA) earned “Overweight” rating by Barclays Capital on Friday, May 13. On Thursday, January 21 the stock rating was initiated by Credit Suisse with “Outperform”.
According to Zacks Investment Research, “Prothena Corporation plc is a biotechnology company focused on the discovery and development of therapeutic monoclonal antibodies for disease-causing proteins. The Company is developing the following programs: NEOD001 for Amyloidosis, NEOD002 for Parkinson’s disease, MCAM for Inflammatory disease and Metastatic Cancer and Tau for Alzheimer’s disease. Prothena Corporation plc is headquartered in Dublin, Ireland.”
Insitutional Activity: The institutional sentiment decreased to 1.04 in Q2 2016. Its down 0.23, from 1.27 in 2016Q1. The ratio worsened, as 13 funds sold all Prothena Corporation PLC shares owned while 40 reduced positions. 11 funds bought stakes while 44 increased positions. They now own 23.97 million shares or 13.54% less from 27.72 million shares in 2016Q1.
Moreover, Citigroup has 0% invested in Prothena Corporation PLC (NASDAQ:PRTA) for 5,509 shares. Credit Suisse Ag, a Switzerland-based fund reported 125,809 shares. Employees Retirement Of Texas has 0.05% invested in the company for 106,000 shares. Mariner Investment holds 33,104 shares or 0.39% of its portfolio. The Ontario – Canada-based Royal Financial Bank Of Canada has invested 0% in Prothena Corporation PLC (NASDAQ:PRTA). Huntington Bank & Trust has 73 shares for 0% of their US portfolio. Smith Asset L P holds 0.01% of its portfolio in Prothena Corporation PLC (NASDAQ:PRTA) for 7,150 shares. Moreover, Hall Laurie J Trustee has 0% invested in Prothena Corporation PLC (NASDAQ:PRTA) for 140 shares. Deutsche Commercial Bank Ag has 73,094 shares for 0% of their US portfolio. Moreover, Blackrock Gru Ltd has 0% invested in Prothena Corporation PLC (NASDAQ:PRTA) for 18,905 shares. Dupont owns 14,475 shares or 0.01% of their US portfolio. Mycio Wealth Ltd Llc last reported 289 shares in the company. Fmr Limited Co reported 5.15M shares or 0.02% of all its holdings. Blackrock Institutional Trust Company Na accumulated 0% or 848,925 shares. Nuveen Asset Mgmt Ltd Liability Co, a Illinois-based fund reported 25,709 shares.
Insider Transactions: Since May 23, 2016, the stock had 0 insider purchases, and 7 selling transactions for $3.29 million net activity. Selkoe Dennis J. sold $273,076 worth of Prothena Corporation PLC (NASDAQ:PRTA) on Monday, August 22. $733,204 worth of Prothena Corporation PLC (NASDAQ:PRTA) was sold by Walker Karin L on Monday, September 19. Kinney Gene G. sold $1.14M worth of stock. HOMAN ARTHUR W also sold $162,991 worth of Prothena Corporation PLC (NASDAQ:PRTA) shares.
More important recent Prothena Corporation PLC (NASDAQ:PRTA) news were published by: Marketwatch.com which released: “/quotes/zigman/3870025/realtime” on April 02, 2013, also Streetinsider.com published article titled: “Form 8-K Prothena Corp plc For: Nov 09”, Fool.com published: “Why Prothena Corporation Plc is Soaring Higher Today” on March 20, 2015. More interesting news about Prothena Corporation PLC (NASDAQ:PRTA) was released by: Streetinsider.com and their article: “Prothena Corp. (PRTA) Announces PRX002 Phase 1b Met Primary Objective in PD …” with publication date: November 09, 2016.
PRTA Company Profile
Prothena Corporation Public Limited Company, incorporated on September 26, 2012, is a global biotechnology company. The Firm is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis (PRX003). The Firm has generated monoclonal antibodies that selectively bind to amyloidogenic (diseased) forms of the Transthyretin (TTR)-mediated amyloidosis (ATTR) protein. The Company’s pipeline also includes late discovery-stage programs for which the Company is testing the efficacy of antibodies in preclinical models of diseases related to amyloid or cell adhesion.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.